Lipid-Based Nanoparticles for Drug Delivery in Cancer

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".

Deadline for manuscript submissions: 31 July 2024 | Viewed by 3287

Special Issue Editors

Department of Drug Science and Technology, University of Turin, 10125 Turin, Italy
Interests: drug delivery systems; solid lipid nanoparticles microemulsions; nanoemulsions; nanostructured lipid carriers; targeting
Department of Drug Science and Technology, University of Turin, 10125 Turin, Italy
Interests: drug delivery systems; solid lipid nanoparticles microemulsions; nanoemulsions; nanostructured lipid carriers; targeting

Special Issue Information

Dear Colleagues,

We are planning to publish a Special Issue based on “Lipid-Based Nanoparticles for Drug Delivery in Cancer” in the journal Pharmaceutics.

Often, cancer chemotherapy encounters several obstacles such as severe side effects, low specificity and stability, and a high incidence of drug-resistant tumor cells. Recently, the attention of researchers has mainly been focused on overcoming multidrug resistance, considered the main cause of chemotherapy failure. The use of nanotechnology and, in particular, of lipid-based nanoparticles as a drug delivery system is promising for avoiding these problems in many tumor types.

Authors are kindly invited to submit original papers, communications, and reviews regarding the potential applications of lipid-based nanocarriers as drug delivery systems for cancer therapy to be published in this Special Issue of Pharmaceutics. We look forward to receiving your contributions.

Dr. Daniela Chirio
Dr. Elena Peira
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

 

Keywords

  • lipid nanoparticles
  • nanocarriers
  • drug delivery systems
  • cancer
  • chemotherapy

Published Papers (3 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

17 pages, 5859 KiB  
Article
Maleimide–Thiol Linkages Alter the Biodistribution of SN38 Therapeutic Microbubbles Compared to Biotin–Avidin While Preserving Parity in Tumoral Drug Delivery
by Nicola Ingram, Radwa H. Abou-Saleh, Amanda D. Race, Paul M. Loadman, Richard J. Bushby, Stephen D. Evans and P. Louise Coletta
Pharmaceutics 2024, 16(3), 434; https://doi.org/10.3390/pharmaceutics16030434 - 21 Mar 2024
Viewed by 386
Abstract
Therapeutic microbubbles (thMBs) contain drug-filled liposomes linked to microbubbles and targeted to vascular proteins. Upon the application of a destructive ultrasound trigger, drug uptake to tumour is improved. However, the structure of thMBs currently uses powerful non-covalent bonding of biotin with avidin-based proteins [...] Read more.
Therapeutic microbubbles (thMBs) contain drug-filled liposomes linked to microbubbles and targeted to vascular proteins. Upon the application of a destructive ultrasound trigger, drug uptake to tumour is improved. However, the structure of thMBs currently uses powerful non-covalent bonding of biotin with avidin-based proteins to link both the liposome to the microbubble (MB) and to bind the targeting antibody to the liposome–MB complex. This linkage is not currently FDA-approved, and therefore, an alternative, maleimide–thiol linkage, that is currently used in antibody–drug conjugates was examined. In a systematic manner, vascular endothelial growth factor receptor 2 (VEGFR2)-targeted MBs and thMBs using both types of linkages were examined for their ability to specifically bind to VEGFR2 in vitro and for their ultrasound imaging properties in vivo. Both showed equivalence in the production of the thMB structure, in vitro specificity of binding and safety profiles. In vivo imaging showed subtle differences for thMBs where biotin thMBs had a faster wash-in rate than thiol thMBs, but thiol thMBs were longer-lived. The drug delivery to tumours was also equivalent, but interestingly, thiol thMBs altered the biodistribution of delivery away from the lungs and towards the liver compared to biotin thMBs, which is an improvement in biosafety. Full article
(This article belongs to the Special Issue Lipid-Based Nanoparticles for Drug Delivery in Cancer)
Show Figures

Graphical abstract

14 pages, 2304 KiB  
Article
In Vitro and Preclinical Antitumor Evaluation of Doxorubicin Liposomes Coated with a Cholesterol-Based Trimeric β-D-Glucopyranosyltriazole
by Aline Teixeira Maciel e Silva, Ana Luiza Chaves Maia, Juliana de Oliveira Silva, Sued Eustáquio Mendes Miranda, Talia Silva Cantini, Andre Luis Branco de Barros, Daniel Crístian Ferreira Soares, Mariana Torquato Quezado de Magalhães, Ricardo José Alves and Gilson Andrade Ramaldes
Pharmaceutics 2023, 15(12), 2751; https://doi.org/10.3390/pharmaceutics15122751 - 11 Dec 2023
Viewed by 802
Abstract
The coating of liposomes with polyethyleneglycol (PEG) has been extensively discussed over the years as a strategy for enhancing the in vivo and in vitro stability of nanostructures, including doxorubicin-loaded liposomes. However, studies have shown some important disadvantages of the PEG molecule as [...] Read more.
The coating of liposomes with polyethyleneglycol (PEG) has been extensively discussed over the years as a strategy for enhancing the in vivo and in vitro stability of nanostructures, including doxorubicin-loaded liposomes. However, studies have shown some important disadvantages of the PEG molecule as a long-circulation agent, including the immunogenic role of PEG, which limits its clinical use in repeated doses. In this context, hydrophilic molecules as carbohydrates have been proposed as an alternative to coating liposomes. Thus, this work studied the cytotoxicity and preclinical antitumor activity of liposomes coated with a glycosyl triazole glucose (GlcL-DOX) derivative as a potential strategy against breast cancer. The glucose-coating of liposomes enhanced the storage stability compared to PEG-coated liposomes, with the suitable retention of DOX encapsulation. The antitumor activity, using a 4T1 breast cancer mouse model, shows that GlcL-DOX controlled the tumor growth in 58.5% versus 35.3% for PEG-coated liposomes (PegL-DOX). Additionally, in the preliminary analysis of the GlcL-DOX systemic toxicity, the glucose-coating liposomes reduced the body weight loss and hepatotoxicity compared to other DOX-treated groups. Therefore, GlcL-DOX could be a promising alternative for treating breast tumors. Further studies are required to elucidate the complete GlcL-DOX safety profile. Full article
(This article belongs to the Special Issue Lipid-Based Nanoparticles for Drug Delivery in Cancer)
Show Figures

Figure 1

Review

Jump to: Research

35 pages, 4305 KiB  
Review
Biomimetic Cell-Derived Nanoparticles: Emerging Platforms for Cancer Immunotherapy
by Tingting Hu, Yuezhou Huang, Jing Liu, Chao Shen, Fengbo Wu and Zhiyao He
Pharmaceutics 2023, 15(7), 1821; https://doi.org/10.3390/pharmaceutics15071821 - 26 Jun 2023
Cited by 2 | Viewed by 1437
Abstract
Cancer immunotherapy can significantly prevent tumor growth and metastasis by activating the autoimmune system without destroying normal cells. Although cancer immunotherapy has made some achievements in clinical cancer treatment, it is still restricted by systemic immunotoxicity, immune cell dysfunction, cancer heterogeneity, and the [...] Read more.
Cancer immunotherapy can significantly prevent tumor growth and metastasis by activating the autoimmune system without destroying normal cells. Although cancer immunotherapy has made some achievements in clinical cancer treatment, it is still restricted by systemic immunotoxicity, immune cell dysfunction, cancer heterogeneity, and the immunosuppressive tumor microenvironment (ITME). Biomimetic cell-derived nanoparticles are attracting considerable interest due to their better biocompatibility and lower immunogenicity. Moreover, biomimetic cell-derived nanoparticles can achieve different preferred biological effects due to their inherent abundant source cell-relevant functions. This review summarizes the latest developments in biomimetic cell-derived nanoparticles for cancer immunotherapy, discusses the applications of each biomimetic system in cancer immunotherapy, and analyzes the challenges for clinical transformation. Full article
(This article belongs to the Special Issue Lipid-Based Nanoparticles for Drug Delivery in Cancer)
Show Figures

Figure 1

Back to TopTop